Week in Review in the Health Outcomes and Pharma Pricing Field from HealthEconomics.Com

Ponte Vedra Beach, Florida (PRWEB) February 15, 2013

The top news story available on HealthEconomics.Com explored results of a study by the European Consortium in Healthcare Outcomes (ECHOUTCOME) claiming that the QALY (quality-adjusted life years) has failed as a common metric for assessing cost-benefit of drug therapies. The findings have set off a controversial debate on the continued use of the QALY as a measure for deciding whether or not a drug will be reimbursed by payers or health systems. The QALY is used by NICE (the National Institute for Health and Clinical Excellence) for coverage decisions by the National Health Service in the United Kingdom, as well as by Canada and Australia. Generally if a treatment costs more than

This entry was posted in Most Visited Websites and tagged , , , , , , , , . Bookmark the permalink.

Leave a Reply